Skip to main content

Table 3 Use of anticoagulant agents, antiplatelet agents, and mechanical prophylaxis

From: Incidence of venous thromboembolism and bleeding events in patients with lower extremity orthopedic surgery: a retrospective analysis of a Japanese healthcare database

  TKAa THAa HFSa Rupture of Achilles tendona Simple fracture of lower extremitiesa
  n = 5023 n = 3856 n = 20,991 n = 572 n = 6639
Anticoagulant agents      
 Warfarin 436 (8.7) 219 (5.7) 1462 (7.0) 6 (1.0) 156 (2.3)
 Unfractionated heparin 1369 (27.3) 1358 (35.2) 3574 (17.0) 3 (0.5) 397 (6.0)
 Low molecular weight heparin 803 (16.0) 958 (24.8) 1003 (4.8) 0 (0.0) 47 (0.7)
 Factor Xa inhibitor 3000 (59.7) 1937 (50.2) 3224 (15.4) 3 (0.5) 157 (2.4)
  NOAC s 1443 (28.7) 816 (21.2) 1954 (9.3) 1 (0.2) 64 (1.0)
  Fondaparinux 1570 (31.3) 1126 (29.2) 1280 (6.1) 2 (0.3) 93 (1.4)
 Others 3 (0.1) 2 (0.1) 45 (0.2) 0 (0.0) 4 (0.1)
Antiplatelet agents 870 (17.6) 470 (12.2) 4645 (22.1) 17 (3.0) 513 (7.7)
Mechanical prophylaxis 4663 (92.8) 3583 (92.9) 18,191 (86.7) 308 (53.8) 4875 (73.4)
  1. Other abbreviations are the same as Table 1
  2. NOAC s novel oral anticoagulants (Edoxaban, Dabigatran, Rivaroxaban and Apixaban)
  3. aNo. (%)